Bipolar Disorder

Categories: Mental diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Bipolar Disorder

MalaCards integrated aliases for Bipolar Disorder:

Name: Bipolar Disorder 11 19 42 75 53 5 41 43 14 71
Depression, Bipolar 42 71
Bipolar Depression 11 14
Manic Disorder 11 71
Manic Bipolar Affective Disorder 11
Bipolar Disorder Manic Phase 11
Bipolar Affective Psychosis 42
Major Affective Disorder 1 71
Bipolar Affective Disorder 42
Major Affective Disorder 2 71
Manic Depressive Disorder 11
Bipolar Spectrum Disorder 42
Manic Bipolar I Disorder 11
Manic Depressive Illness 42
Major Affective Disorder 71
Depressive-Manic Psych. 11
Bipolar Disorder, Mixed 71
Mixed Bipolar Disorder 11
Depression Bipolar 53
Manic Depression 11


External Ids:

Disease Ontology 11 DOID:3312
MeSH 43 D001714
ICD10 31 F31
UMLS 71 C0005586 C0005587 C0024713 more

Summaries for Bipolar Disorder

MedlinePlus: 41 What is bipolar disorder? Bipolar disorder is a mood disorder that can cause intense mood swings: Sometimes you may feel extremely "up," elated, irritable, or energized. This is called a manic episode. Other times you may feel "down," sad, indifferent, or hopeless. This is called a depressive episode. You may have both manic and depressive symptoms together. This is called a mixed episode. Along with the mood swings, bipolar disorder causes changes in behavior, energy levels, and activity levels. Bipolar disorder used to be called other names, including manic depression and manic-depressive disorder. What are the types of bipolar disorder? There are three main types of bipolar disorder: Bipolar I disorder involves manic episodes that last at least 7 days or manic symptoms so severe that you need immediate hospital care. Depressive episodes are also common. Those often last at least two weeks. This type of bipolar disorder can also involve mixed episodes. Bipolar II disorder involves depressive episodes. But instead of full-blown manic episodes, there are episodes of hypomania. Hypomania is a less severe version of mania. Cyclothymic disorder, or cyclothymia, also involves hypomanic and depressive symptoms. But they are not as intense or as long-lasting as hypomanic or depressive episodes. The symptoms usually last for at least two years in adults and for one year in children and teenagers. With any of these types, having four or more episodes of mania or depression in a year is called "rapid cycling." What causes bipolar disorder? The exact cause of bipolar disorder is unknown. Several factors likely play a role in the disorder. They include genetics, brain structure and function, and your environment. Who is at risk for bipolar disorder? You are at higher risk for bipolar disorder if you have a close relative who has it. Going through trauma or stressful life events may raise this risk even more. What are the symptoms of bipolar disorder? The symptoms of bipolar disorder can vary. But they involve mood swings known as mood episodes: The symptoms of a manic episode can include Feeling very up, high, or elated Feeling jumpy or wired, more active than usual Having a very short temper or seeming extremely irritable Having racing thoughts and talking very fast Needing less sleep Feeling like you are unusually important, talented, or powerful Do risky things that show poor judgment, such as eating and drinking too much, spending or giving away a lot of money, or having reckless sex The symptoms of a depressive episode can include Feeling very sad, hopeless, or worthless Feeling lonely or isolating yourself from others Talking very slowly, feeling like you have nothing to say, or forgetting a lot Having little energy Sleeping too much Eating too much or too little Lack of interest in your usual activities and being unable to do even simple things Thinking about death or suicide The symptoms of a mixed episode include both manic and depressive symptoms together. For example, you may feel very sad, empty, or hopeless, while at the same time feeling extremely energized. Some people with bipolar disorder may have milder symptoms. For example, you may have hypomania instead of mania. With hypomania, you may feel very good and find that you can get a lot done. You may not feel like anything is wrong. But your family and friends may notice your mood swings and changes in activity levels. They may realize that your behavior is unusual for you. After the hypomania, you might have severe depression. Your mood episodes may last a week or two or sometimes longer. During an episode, symptoms usually occur every day for most of the day. How is bipolar disorder diagnosed? To diagnose bipolar disorder, your health care provider may use many tools: A physical exam A medical history, which will include asking about your symptoms, lifetime history, experiences, and family history Medical tests to rule out other conditions A mental health evaluation. Your provider may do the evaluation or may refer you to a mental health specialist to get one. What are the treatments for bipolar disorder? Treatment can help many people, including those with the most severe forms of bipolar disorder. The main treatments for bipolar disorder include medicines, psychotherapy, or both: Medicines can help control the symptoms of bipolar disorder. You may need to try several different medicines to find which one works best for you. Some people need to take more than one medicine. It's important to take your medicine consistently. Don't stop taking it without first talking with your provider. Contact your provider if you have any concerns about side effects from the medicines. Psychotherapy (talk therapy) can help you recognize and change troubling emotions, thoughts, and behaviors. It can give you and your family support, education, skills, and coping strategies. There are several different types of psychotherapy that may help with bipolar disorder. Other treatment options include Electroconvulsive therapy (ECT), a brain stimulation procedure that can help relieve symptoms. ECT is most often used for severe bipolar disorder that is not getting better with other treatments. It may also be used when someone needs a treatment that will work more quickly than medicines. This might be when a person has a high risk of suicide or is catatonic (unresponsive). Getting regular aerobic exercise may help with depression, anxiety, and trouble sleeping Keeping a life chart can help you and your provider track and treat your bipolar disorder. A life chart is a record of your daily mood symptoms, treatments, sleep patterns, and life events. Bipolar disorder is a lifelong illness. But long-term, ongoing treatment can help manage your symptoms and enable you to live a healthy, successful life. NIH: National Institute of Mental Health

MalaCards based summary: Bipolar Disorder, also known as depression, bipolar, is related to bipolar i disorder and schizophrenia. An important gene associated with Bipolar Disorder is MAFD1 (Major Affective Disorder 1), and among its related pathways/superpathways are Neurotransmitter clearance and Methylphenidate Pathway, Pharmacodynamics. The drugs Coal tar and Eleuthero have been mentioned in the context of this disorder. Affiliated tissues include brain, prefrontal cortex and eye, and related phenotype is Increased shRNA abundance (Z-score > 2).

MedlinePlus Genetics: 42 Bipolar disorder is a mental health condition that causes extreme shifts in mood, energy, and behavior. This disorder most often appears in late adolescence or early adulthood, although symptoms can begin at any time of life.People with bipolar disorder experience both dramatic "highs," called manic episodes, and "lows," called depressive episodes. These episodes can last from hours to weeks, and many people have no symptoms between episodes.Manic episodes are characterized by increased energy and activity, irritability, restlessness, an inability to sleep, and reckless behavior. Some people with bipolar disorder experience hypomanic episodes, which are similar to but less extreme than manic episodes.Depressive episodes are marked by low energy and activity, a feeling of hopelessness, and an inability to perform everyday tasks. People with bipolar disorder often have repeated thoughts of death and suicide, and they have a much greater risk of dying by suicide than the general population.Manic and depressive episodes can include psychotic symptoms, such as false perceptions (hallucinations) or strongly held false beliefs (delusions). Mixed episodes, which have features of manic and depressive episodes at the same time, also occur in some affected individuals.Bipolar disorder is classified into several types based on the mood changes that occur. Bipolar I involves manic episodes, which can be accompanied by psychotic symptoms, and hypomanic or depressive episodes. Bipolar II involves hypomanic episodes and depressive episodes. Cyclothymic disorder involves hypomanic episodes and depressive episodes that are typically less severe than those in bipolar I or bipolar II.Bipolar disorder often occurs with other mental health conditions, including anxiety disorders (such as panic attacks), behavioral disorders (such as attention-deficit/hyperactivity disorder), and substance abuse.

Disease Ontology: 11 A mood disorder that involves alternating periods of mania and depression.

Wikipedia: 75 Bipolar disorder, previously known as manic depression, is a mental disorder characterized by periods of... more...

Related Diseases for Bipolar Disorder

Diseases in the Bipolar Disorder family:

Bipolar Ll Disorder Bipolar I Disorder

Diseases related to Bipolar Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 916)
# Related Disease Score Top Affiliating Genes
1 bipolar i disorder 33.5 SLC6A4 PRODH DISC1 DAOA COMT
2 schizophrenia 33.4 SLC6A4 PRODH NRG1 IMPA2 IMPA1 DRD3
3 mood disorder 33.3 SLC6A4 PRODH NRG1 IMPA2 IMPA1 DRD3
4 psychotic disorder 33.3 SLC6A4 PRODH NRG1 DRD3 DISC1 DAOA
5 major depressive disorder 33.2 SLC6A4 DRD3 DISC2 DISC1 COMT
6 schizoaffective disorder 33.0 SLC6A4 PRODH DRD3 DISC2 DISC1 DAOA
7 attention deficit-hyperactivity disorder 32.8 SLC6A4 PRODH NRG1 DRD3 DISC1 COMT
8 cyclothymic disorder 32.7 SLC6A4 DISC1 DAOA COMT
9 anxiety 32.6 SLC6A4 PRODH DRD3 DISC1 COMT
10 personality disorder 32.5 SLC6A4 DRD3 COMT
11 substance abuse 32.5 SLC6A4 PRODH DRD3 COMT
12 tardive dyskinesia 32.4 DISC1 COMT
13 alcohol use disorder 32.4 SLC6A4 PRODH DRD3 COMT
14 schizophrenia 18 32.3 PRODH DISC1
15 panic disorder 32.2 SLC6A4 DRD3 DAOA-AS1 DAOA COMT
16 schizophrenia 2 32.2 PRODH DISC2 DISC1
17 autism 32.0 SLC6A4 PRODH NRG1 DRD3 DISC1 COMT
18 obsessive-compulsive disorder 31.9 SLC6A4 DRD3 COMT
19 oppositional defiant disorder 31.9 SLC6A4 DRD3 COMT
20 disease of mental health 31.9 SLC6A4 PRODH DRD3 DISC1 COMT
21 generalized anxiety disorder 31.8 SLC6A4 PRODH COMT
22 autism spectrum disorder 31.8 SLC6A4 PRODH NRG1 DRD3 DISC2 COMT
23 substance dependence 31.7 SLC6A4 DRD3 COMT
24 tobacco addiction 31.7 SLC6A4 DRD3 COMT
25 social phobia 31.7 SLC6A4 PRODH COMT
26 dysthymic disorder 31.5 SLC6A4 PRODH COMT
27 cannabis abuse 31.5 SLC6A4 PRODH NRG1 DISC1 COMT
28 schizophrenia 1 31.5 DISC1 DAOA
29 agoraphobia 31.5 SLC6A4 PRODH COMT
30 gilles de la tourette syndrome 31.4 SLC6A4 DRD3 COMT
31 cocaine dependence 31.3 SLC6A4 DRD3 COMT
32 neurotic disorder 31.3 SLC6A4 COMT
33 phobia, specific 31.3 SLC6A4 PRODH COMT
34 paranoid schizophrenia 31.3 SLC6A4 PRODH DRD3 DISC1 COMT
35 schizophreniform disorder 31.3 PRODH NRG1 DRD3 DISC1 DAOA COMT
36 melancholia 31.2 SLC6A4 COMT
37 chromosome 22q11.2 deletion syndrome, distal 31.2 PRODH NRG1 DISC1 COMT
38 tic disorder 31.2 SLC6A4 PRODH DRD3 COMT
39 pervasive developmental disorder 31.2 SLC6A4 PRODH DISC1
40 separation anxiety disorder 31.2 SLC6A4 COMT
41 drug dependence 31.2 SLC6A4 DRD3 COMT
42 opiate dependence 31.1 SLC6A4 DRD3 COMT
43 pathological gambling 31.1 SLC6A4 DRD3 COMT
44 schizotypal personality disorder 31.1 PRODH NRG1 DISC1 DAOA COMT
45 movement disease 31.0 PRODH DRD3 COMT
46 velocardiofacial syndrome 31.0 PRODH NRG1 DISC1 COMT
47 asperger syndrome 31.0 SLC6A4 DISC1 COMT
48 alexithymia 31.0 SLC6A4 COMT
49 impulse control disorder 31.0 SLC6A4 DRD3 COMT
50 postpartum depression 30.9 SLC6A4 COMT

Comorbidity relations with Bipolar Disorder via Phenotypic Disease Network (PDN):

Acute Cystitis Diabetes Insipidus, Nephrogenic, 2, Autosomal
Hypertension, Essential Hypothyroidism
Major Affective Disorder 9 Major Depressive Disorder
Parkinson Disease, Late-Onset Schizophrenia
Schizophreniform Disorder Tardive Dyskinesia

Graphical network of the top 20 diseases related to Bipolar Disorder:

Diseases related to Bipolar Disorder

Symptoms & Phenotypes for Bipolar Disorder

GenomeRNAi Phenotypes related to Bipolar Disorder according to GeneCards Suite gene sharing:

25 (show all 14)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.53 IMPA2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.53 IMPA2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.53 ATP2A2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.53 DRD3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-174 9.53 ATP2A2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.53 ATP2A2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.53 ATP2A2
8 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.53 IMPA2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.53 ATP2A2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-33 9.53 IMPA2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.53 ATP2A2 DRD3 IMPA2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.53 ATP2A2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-58 9.53 DRD3
14 Increased shRNA abundance (Z-score > 2) GR00366-A-86 9.53 ATP2A2

Drugs & Therapeutics for Bipolar Disorder

Drugs for Bipolar Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 407)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Coal tar Approved Phase 4 8007-45-2
Eleuthero Approved, Experimental Phase 4
Memantine Approved, Investigational Phase 4 41100-52-1, 19982-08-2 4054
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
Ondansetron Approved, Withdrawn Phase 4 99614-02-5 4595
Acamprosate Approved, Investigational Phase 4 77337-73-6, 77337-76-9 71158
Topiramate Approved Phase 4 97240-79-4 5284627
Exenatide Approved, Investigational Phase 4 141758-74-9 45588096
Galantamine Approved Phase 4 357-70-0, 1953-04-4 9651
Inositol Approved, Investigational, Withdrawn Phase 4 87-89-8
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
Cocaine Approved, Illicit Phase 4 50-36-2 446220 5760
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
Oxcarbazepine Approved Phase 4 28721-07-5 34312
Pramipexole Approved, Investigational Phase 4 104632-26-0, 104632-25-9, 104632-28-2 4885 119570 59868
Iloperidone Approved Phase 4 133454-47-4 71360
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
Ropinirole Approved, Investigational Phase 4 91374-21-9 5095
Tranylcypromine Approved, Investigational Phase 4 155-09-9 5530 441233
Histamine Approved, Investigational Phase 4 51-45-6 774
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
Nortriptyline Approved Phase 4 72-69-5 4543
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
Chlorpromazine Approved, Investigational, Vet_approved Phase 4 69-09-0, 50-53-3 2726
Benzatropine Approved Phase 4 86-13-5 1201549
Brexpiprazole Approved, Investigational Phase 4 913611-97-9 11978813
Sibutramine Approved, Illicit, Investigational, Withdrawn Phase 4 106650-56-0 5210
Simvastatin Approved Phase 4 79902-63-9 54454
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
Donepezil Approved Phase 4 120014-06-4 3152
Losartan Approved Phase 4 114798-26-4 3961
Nicotine Approved Phase 4 54-11-5 942 89594
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
Vortioxetine Approved, Investigational Phase 4 508233-74-7 9966051
Succinylcholine Approved Phase 4 306-40-1, 71-27-2 5314
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
Lorazepam Approved Phase 4 846-49-1 3958
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
Etomidate Approved Phase 4 33125-97-2 667484
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
Dextroamphetamine Approved, Illicit, Investigational Phase 4 51-64-9, 300-62-9 5826 3007
Mecobalamin Approved, Investigational Phase 4 13422-55-4
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 44475014
Clozapine Approved Phase 4 5786-21-0 2818 135398737
Amiloride Approved Phase 4 17440-83-4, 2016-88-8, 2609-46-3 16231
Sertraline Approved Phase 4 79617-96-2 68617

Interventional clinical trials:

(show top 50) (show all 1337)
# Name Status NCT ID Phase Drugs
1 A Randomized Controlled Trial to Evaluate the Effectiveness of Clozapine Versus Olanzapine, Quetiapine or Risperidone in Treatment Resistant Bipolar Disorder Unknown status NCT02562287 Phase 4 Clozapine;Risperidone;Olanzapine;Quetiapine
2 An Open Label, Multicenter, Single Arm, 4-Week Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4 quetiapine fumarate tablet (Seroquel)
3 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia by Aripiprazole Add-on Therapy in the Treatment of Schizophrenia and Bipolar Disorder: An Open-Label Trial Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
4 Assessment and Follow Up Study of Children and Adolescent With Bipolar Disorder Unknown status NCT01000402 Phase 4 Psychopharmacotherapy
5 Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder Unknown status NCT00608075 Phase 4 lithium;Lithium
6 Open Label Prophylaxis Study of Lithium Plus Extended- Release Carbamazepine (Equetro®) Combination for Rapid Cycling Bipolar Disorder Unknown status NCT00325286 Phase 4 Lithium Plus Extended- Release Carbamazepine
7 Algorithm Guided Treatment Strategies for Bipolar Depression Unknown status NCT01938859 Phase 4 Lithium;Quetiapine;Shuganjieyu capsule
8 Effects of N-Acetyl-Cysteine on Oxidative Stress Biomarkers in Bipolar Patients With and Without Tobacco Use Disorder Unknown status NCT02252341 Phase 4
9 Comparative Efficacy and Acceptability of Lithium, Valproate, Oxcarbazepine, Quetiapine, Olanzapine, and Ziprasidone in Bipolar I Disorder, Manic or Mixed Phase Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
10 A Multicenter, 52-week, Provider- Randomized, Pragmatic Trial to Assess the Differences in ABILIFY MYCITE - a Digital Medicine System (DMS) Versus Treatment as Usual (TAU) for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole Unknown status NCT03881449 Phase 4
11 A Double Blind Study To Evaluate the Dose Tolerance and Safety of Equetro (Carbamazepine) Versus Placebo Followed by a Long-Term Maintenance in Children and Adolescents Aged 10-17 Years With Acute Manic or Mixed Bipolar I Disorder Unknown status NCT02623504 Phase 4 Carbamazepine;Placebo
12 Clinical Psychopharmacology Division Institute of Mental Health, Peking University Unknown status NCT03148535 Phase 4 Lithium Carbonate;lithium carbonate combined with SSRI antidepressant treatment
13 An Exploratory Randomized Open Comparison of Oxtellar XR® vs Oxcarbazepine IR (Trileptal®) for the Treatment of Bipolar Depression Unknown status NCT03567681 Phase 4 Extended release oxcarbazepine vs Immediate release oxcarbazepine
14 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar I and II Depression. Unknown status NCT00335205 Phase 4 ropinirole
15 Assessing the Efficacy of Left Repetitive Transcranial Magnetic Stimulation (rTMS) as an Adjunctive Treatment to Mood Stabilizers for the Treatment of Bipolar Depression Unknown status NCT01583023 Phase 4 Bupropion
16 Exploring Alterations of Central Autonomic Modulation in Patients With Bipolar Depression Unknown status NCT01213121 Phase 4 Quetiapine
17 Reduction of Cardiovascular Risk in Severe Mental Illness Prescribing and Using Better and More Appropriated Drugs Unknown status NCT01182012 Phase 4
18 An Open Label, 4-Week, Randomised, Multi-Centre, Phase IV Study to Compare the Efficacy and Safety of Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder Completed NCT00672490 Phase 4 Quetiapine Fumarate;Lithium
19 Protective Effect of Valproate on Brain Cells:A Magnetic Resonance Imaging and Spectroscopy Study in Patients With Bipolar Disorder Diagnosis Completed NCT00431522 Phase 4 Valproic acid, sodium salt
20 Lithium Use for Bipolar Disorder (LiTMUS): A Randomized Controlled Effectiveness Trial Completed NCT00667745 Phase 4 Lithium Carbonate;Optimized Treatment (OPT)
21 Metformin for Treatment Antipsychotic-induced Metabolic Syndrome in Bipolar Disorder Patients Completed NCT02644577 Phase 4 Metformin
22 Ondansetron for Bipolar Disorder and Alcohol Use Disorders Completed NCT02082678 Phase 4 Ondansetron;Placebo
23 A Phase IV STudy of the Effectiveness of Quetiapine Extended Release 600mg Once a Day to Control the Symptoms of Manic Phase of Bipolar Disorder. Completed NCT00521365 Phase 4 Quetiapine 600mg
24 A Double-Blind, Randomized, Placebo-Controlled Trial of Acamprosate in Alcohol-Dependent Individuals With Comorbid Bipolar Disorder Completed NCT00466661 Phase 4 Acamprosate;Placebo
25 A Double Blind, Randomized, Placebo Controlled Trial of Aripiprazole Plus Valproate in the Short-Term and Long-Term Treatment of Bipolar Disorder Completed NCT00484471 Phase 4 aripiprazole;valproate;placebo
26 A Double-Blind, Randomized, Placebo-Controlled, Pilot Study of Topiramate vs. Placebo in Combination With Olanzapine for the Prevention of Weight Gain in Manic or Mixed Youth With Bipolar Disorder Completed NCT00394095 Phase 4 Topiramate;Placebo
27 A Double-Blind Placebo-Controlled Study of Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults With Bipolar Disorder, Major Depressive Disorder, Schizophrenia or Schizoaffective Disorder Completed NCT00845507 Phase 4 Exenatide;Placebo
28 Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance Completed NCT00835120 Phase 4 Pioglitazone
29 The Efficacy and Safety of Galantamine for Dysfunction in Bipolar Disorder Completed NCT00741598 Phase 4 Galantamine-ER;Galantamine placebo
30 A Double-Blind, Randomized, Placebo-Controlled Trial of Ramelteon for the Treatment of Insomnia and Mood Stability in Patients With Euthymic Bipolar Disorder. Completed NCT00552760 Phase 4 Ramelteon;Placebo
31 Targeting Circadian and Cognitive Dysfunction in Bipolar Disorder With Modafinil Completed NCT01965925 Phase 4 Modafinil;Placebo
32 Longitudinal Study on the Neuroprotective and Neurotrophic Effects of Lithium in Bipolar Disorder: Identification of Cellular and Molecular Targets Clinically Relevant Completed NCT01919892 Phase 4 Lithium
33 18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder Completed NCT03902613 Phase 4 Lurasidone
34 Effect of Regulated Add -on Sodium Chloride Intake on Stabilization of Serum Lithium Concentration in Bipolar Disorder: A Randomized Controlled Trial Completed NCT04222816 Phase 4 Lithium Carbonate;Sodium chloride
35 Adjunctive Ziprasidone in Overweight and Obese Patients With Bipolar Disorder Completed NCT00472641 Phase 4 Ziprasidone/Geodon
36 Multi-center, Double-blind, Randomized, Comparative Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of Abilify and Depakote in 24-week Treatment of Mania in Patients With Bipolar Disorder Remitted After 6-week Treatment With Abilify and Depakote Completed NCT00545675 Phase 4 Abilify(aripiprazole);Depakote (divalproate)
37 Multi-center, Single Arm, Open Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of Abilify With Depakote in the 6-week Treatment of Acute Mania in Patients With Bipolar Disorder Completed NCT00545142 Phase 4 Abilify(Aripiprazole);Depakote(Divalproate)
38 Quetiapine for Bipolar Disorder and Alcohol Dependence Completed NCT00457197 Phase 4 Placebo;Quetiapine
39 A Multi-center, Randomized, Double-blind, Parallel Group, Placebo-controlled 52 Weeks Clinical Trial to Evaluate Efficacy and Safety of Oxcarbazepine p.o.(300-1200 mg/Day) as Adjuvant Therapy in the Bipolar Disorder I or II Treatment Completed NCT00154323 Phase 4 Oxcarbazepine
40 Open Label Study of Iloperidone (IL) as Adjunctive Treatment in Mixed States (MS) of Bipolar Disorder (BD) Completed NCT02413918 Phase 4 iloperidone
41 Memantine and Cognitive Dysfunction in Bipolar Disorder Completed NCT00586066 Phase 4 Memantine;Placebo
42 A Randomized, Double-blind, Placebo-controlled Study of Quetiapine SR and Divalproex Sodium ER on Anxiety in Bipolar Disorder With at Least Moderately Severe Current Anxiety and Lifetime Panic or Generalized Anxiety Disorder. Completed NCT00579280 Phase 4 quetiapine SR;divalproex sodium ER;placebo
43 Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder? Completed NCT00571688 Phase 4 Risperdal (risperidone) Consta;Treatment as usual
44 A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Current at Least Moderately Severe Anxiety and Lifetime Panic Disorder or Generalized Anxiety Disorder Completed NCT00167479 Phase 4 risperidone (Risperdal)
45 Treatment and Outcome of Early Onset Bipolar Disorder Completed NCT00048802 Phase 4 Lithium;Olanzapine;Divalproex;Risperidone;Quetiapine;Ziprasidone;Aripriprazole
46 A Double-Blind, Placebo-Controlled Trial of Lamotrigine In Individuals With Bipolar Disorder and Comorbid Alcohol Dependence Completed NCT01015586 Phase 4 Lamotrigine;Placebo
47 Varenicline Treatment for Smoking Cessation in Patients With Bipolar Disorder Completed NCT01010204 Phase 4 Varenicline;Placebo
48 Enhancing Adherence and Outcomes in Bipolar Disorder With Abilify Maintena + a Targeted Behavioral Approach to Promote Sustained Adherence and Behavioral Change Completed NCT03408873 Phase 4 Abilify Maintena
49 Pramipexole in Bipolar Disorder: Targeting Cognition (PRAM-BD) Completed NCT02397837 Phase 4 Pramipexole;Placebo
50 Lamictal for Use in Treatment of Bipolar Disorder In Adults. A Practical Clinical Assessment of Tolerability and Clinical Effectiveness. Completed NCT00067938 Phase 4 lamotrigine

Search NIH Clinical Center for Bipolar Disorder

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Divalproex Sodium
gabapentin enacarbil
Lithium Aspartate
Lithium Carbonate
lithium citrate
Mylan brand of clozapine
Quetiapine fumarate
Sodium Valproate
Tiagabine hydrochloride
UDL brand of clozapine
Valproic Acid

Cochrane evidence based reviews: bipolar disorder

Genetic Tests for Bipolar Disorder

Anatomical Context for Bipolar Disorder

Organs/tissues related to Bipolar Disorder:

MalaCards : Brain, Prefrontal Cortex, Eye, Cingulate Cortex, Cortex, Amygdala, Heart

Publications for Bipolar Disorder

Articles related to Bipolar Disorder:

(show top 50) (show all 34655)
# Title Authors PMID Year
Comparing the effectiveness of imagery focussed cognitive therapy to group psychoeducation for patients with bipolar disorder: A randomised trial. 62 41
36206888 2023
Positive moods are all alike? Differential affect amplification effects of 'elated' versus 'calm' mental imagery in young adults reporting hypomanic-like experiences. 62 41
36261422 2022
Sublingual Dexmedetomidine for Agitation Associated with Schizophrenia or Bipolar Disorder: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed. 62 41
36002761 2022
Increased neurotrophin-3 in drug-free subjects with bipolar disorder during manic and depressive episodes. 53 62
20060128 2010
Analysis of a polymorphic microRNA target site in the purinergic receptor P2RX7 gene. 53 62
20446288 2010
Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depression. 53 62
20067857 2010
Differential association of circadian genes with mood disorders: CRY1 and NPAS2 are associated with unipolar major depression and CLOCK and VIP with bipolar disorder. 53 62
20072116 2010
Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression. 53 62
20080186 2010
DISC1 duplication in two brothers with autism and mild mental retardation. 53 62
20002455 2010
Association of polymorphisms of the tryptophan hydroxylase 2 gene with risk for bipolar disorder or suicidal behavior. 53 62
19800079 2010
Allele specific analysis of the ADRBK2 gene in lymphoblastoid cells from bipolar disorder patients. 53 62
19766236 2010
Association between Serotonin-Related Polymorphisms in 5HT2A, TPH1, TPH2 Genes and Bipolar Disorder in Korean Population. 53 62
20396435 2010
Association analyses between brain-expressed fatty-acid binding protein (FABP) genes and schizophrenia and bipolar disorder. 53 62
19554614 2010
Translin-associated factor X gene (TSNAX) may be associated with female major depressive disorder in the Japanese population. 53 62
19760522 2010
Higher striatal dopamine transporters in euthymic patients with bipolar disorder: a SPECT study with [Tc] TRODAT-1. 53 62
20148872 2010
N-methyl-D-aspartate receptor expression in parvalbumin-containing inhibitory neurons in the prefrontal cortex in bipolar disorder. 53 62
20148871 2010
Mutation screening and assessment of the effect of genetic variations on expression and RNA editing of serotonin receptor 2C in the human brain. 53 62
20015120 2010
Met carriers of BDNF Val66Met genotype show increased N-acetylaspartate concentration in the anterior cingulate cortex. 53 62
19683059 2010
Positive association between the brain-derived neurotrophic factor (BDNF) gene and bipolar disorder in the Han Chinese population. 53 62
19330778 2010
Association study of PDE4B gene variants in Scandinavian schizophrenia and bipolar disorder multicenter case-control samples. 53 62
19350560 2010
NK1 (TACR1) receptor gene 'knockout' mouse phenotype predicts genetic association with ADHD. 53 62
19204064 2010
Catechol-O-methyltransferase Val158Met polymorphism affects therapeutic response to mood stabilizer in symptomatic manic patients. 53 62
20004480 2010
NRG1 gene in recurrent major depression: no association in a large-scale case-control association study. 53 62
19367584 2010
Genetics of attention-deficit hyperactivity disorder (ADHD). 53 62
19715710 2009
State-dependent decrease in levels of brain-derived neurotrophic factor in bipolar disorder: a meta-analytic study. 53 62
19786073 2009
Genetic variation in neuregulin1 is associated with differences in prefrontal engagement in children. 53 62
19449332 2009
Levels of neuregulin 1 and 3 proteins in Brodmann's area 46 from subjects with schizophrenia and bipolar disorder. 53 62
19765633 2009
The effect of COMT, BDNF, 5-HTT, NRG1 and DTNBP1 genes on hippocampal and lateral ventricular volume in psychosis. 53 62
19573260 2009
Glucocorticoid receptor polymorphisms in major depression. Focus on glucocorticoid sensitivity and neurocognitive functioning. 53 62
19906241 2009
Serum brain-derived neurotrophic factor in bipolar and unipolar depression: a potential adjunctive tool for differential diagnosis. 53 62
19501841 2009
Association between the serotonin 2A receptor gene and bipolar affective disorder in an Australian cohort. 53 62
19584773 2009
Association studies and gene expression analyses of the DISC1-interacting molecules, pericentrin 2 (PCNT2) and DISC1-binding zinc finger protein (DBZ), with schizophrenia and with bipolar disorder. 53 62
19191256 2009
The Val/Met functional polymorphism in COMT confers susceptibility to bipolar disorder: evidence from an association study and a meta-analysis. 53 62
19578924 2009
Common and rare variants of DAOA in bipolar disorder. 53 62
19194963 2009
Genetic variation in the G72 (DAOA) gene affects temporal lobe and amygdala structure in subjects affected by bipolar disorder. 53 62
19689504 2009
Cognitive function and serum levels of brain-derived neurotrophic factor in patients with bipolar disorder. 53 62
19689509 2009
Phosphorylation status of glucocorticoid receptor, heat shock protein 70, cytochrome c and Bax in lymphocytes of euthymic, depressed and manic bipolar patients. 53 62
19359101 2009
No association between lithium full responders and the DRD1, DRD2, DRD3, DAT1, 5-HTTLPR and HTR2A genes in a Sardinian sample. 53 62
19647327 2009
Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients. 53 62
19473667 2009
DISC1 association, heterogeneity and interplay in schizophrenia and bipolar disorder. 53 62
18317464 2009
Association of the dystrobrevin binding protein 1 gene (DTNBP1) in a bipolar case-control study (BACCS). 53 62
19089808 2009
Positron emission tomography quantification of serotonin-1A receptor binding in medication-free bipolar depression. 53 62
19278673 2009
The use of triiodothyronine as an augmentation agent in treatment-resistant bipolar II and bipolar disorder NOS. 53 62
19215985 2009
Changes in gyrification over 4 years in bipolar disorder and their association with the brain-derived neurotrophic factor valine(66) methionine variant. 53 62
19167700 2009
Preliminary evidence on the association between XBP1-116C/G polymorphism and response to prophylactic treatment with valproate in bipolar disorders. 53 62
19564049 2009
Serotonin receptor 2C and mental disorders: genetic, expression and RNA editing studies. 53 62
19411841 2009
[An association study of brain-derived neurotrophic factor gene polymorphism in bipolar disorders]. 53 62
19953912 2009
Family-based association study of Neuregulin 1 with psychotic bipolar disorder. 53 62
19127563 2009
Exploration of the one-bead one-compound methodology for the design of prolyl oligopeptidase substrates. 53 62
19593439 2009
Evidence for the association of the DAOA (G72) gene with schizophrenia and bipolar disorder but not for the association of the DAO gene with schizophrenia. 53 62
19586533 2009

Variations for Bipolar Disorder

ClinVar genetic disease variations for Bipolar Disorder:

# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CLCN2 NM_004366.6(CLCN2):c.740G>T (p.Gly247Val) SNV Uncertain Significance
523471 rs1553856477 GRCh37: 3:184075440-184075440
GRCh38: 3:184357652-184357652

Copy number variations for Bipolar Disorder from CNVD:

6 (show top 50) (show all 399)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13918 1 100964950 101093664 Deletion Bipolar disorder
2 13959 1 101777242 101789688 Copy number Bipolar disorder
3 14276 1 106411328 106634702 Copy number Bipolar disorder
4 15012 1 111824223 111936532 Deletion Bipolar disorder
5 15144 1 112987422 113369070 Deletion Bipolar disorder
6 15198 1 113388739 114043773 Deletion Bipolar disorder
7 15265 1 114105331 114260861 Deletion Bipolar disorder
8 15293 1 114379103 114611497 Deletion Bipolar disorder
9 15315 1 114627212 115118807 Deletion Bipolar disorder
10 17285 1 142400000 148000000 Deletion Bipolar disorder
11 17371 1 142600000 147000000 Copy number Bipolar disorder
12 17555 1 14341488 14762438 Deletion Bipolar disorder
13 18108 1 144093481 144503421 Deletion Bipolar disorder
14 24355 1 179082079 179207535 Deletion Bipolar disorder
15 27840 1 214001144 214182688 Deletion Bipolar disorder
16 30012 1 239069843 239226340 Deletion Bipolar disorder
17 30852 1 246404335 246667943 Deletion Bipolar disorder
18 30991 1 247034191 247138092 Deletion Bipolar disorder
19 31736 1 30336050 30952188 Deletion Bipolar disorder
20 34240 1 53925291 53984359 Copy number GLIS1 Bipolar disorder
21 35075 1 59854502 60323099 Deletion Bipolar disorder
22 35289 1 62052182 62289893 Deletion Bipolar disorder
23 35951 1 696962 803181 Deletion Bipolar disorder
24 37047 1 84784450 84864145 Copy number CTBS Bipolar disorder
25 37048 1 84784450 84864145 Copy number SPATA1 Bipolar disorder
26 37147 1 85996510 86164671 Deletion Bipolar disorder
27 38265 10 10058972 10215130 Deletion Bipolar disorder
28 39159 10 111195021 111323778 Deletion Bipolar disorder
29 39762 10 119100000 135374737 Deletion Bipolar disorder
30 40469 10 128361479 128559816 Deletion Bipolar disorder
31 42381 10 32899498 33000799 Deletion Bipolar disorder
32 42648 10 37554667 37710375 Deletion Bipolar disorder
33 43112 10 44523027 44679489 Copy number Bipolar disorder
34 43587 10 47013328 47173619 Copy number Bipolar disorder
35 44374 10 56148428 56359760 Deletion Bipolar disorder
36 47196 10 90344868 90556337 Deletion Bipolar disorder
37 47223 10 90559662 90957411 Deletion Bipolar disorder
38 49063 11 102652001 102778728 Deletion Bipolar disorder
39 50159 11 114721884 114868905 Deletion Bipolar disorder
40 51811 11 131159857 131261275 Deletion Bipolar disorder
41 51869 11 132518807 132864395 Deletion Bipolar disorder
42 51963 11 133786141 134449982 Deletion Bipolar disorder
43 53165 11 25250128 26084796 Deletion Bipolar disorder
44 53245 11 26949271 27197653 Deletion Bipolar disorder
45 53370 11 28011741 28338552 Deletion Bipolar disorder
46 53647 11 31510470 31740158 Deletion Bipolar disorder
47 54087 11 36668226 36773732 Deletion Bipolar disorder
48 54480 11 4481014 4590667 Deletion Bipolar disorder
49 54844 11 4760556 4866960 Deletion Bipolar disorder
50 55263 11 50343409 51228612 Copy number Bipolar disorder

Expression for Bipolar Disorder

Search GEO for disease gene expression data for Bipolar Disorder.

Pathways for Bipolar Disorder

GO Terms for Bipolar Disorder

Cellular components related to Bipolar Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 GABA-ergic synapse GO:0098982 8.92 NRG1 DRD3 DISC1

Biological processes related to Bipolar Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 inositol phosphate dephosphorylation GO:0046855 9.62 IMPA2 IMPA1
2 dopamine metabolic process GO:0042417 9.56 DRD3 COMT
3 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.33 NRG1 DRD3
4 inositol metabolic process GO:0006020 9.26 IMPA2 IMPA1
5 inositol biosynthetic process GO:0006021 8.92 IMPA2 IMPA1

Molecular functions related to Bipolar Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 inositol monophosphate 4-phosphatase activity GO:0052833 9.56 IMPA2 IMPA1
2 inositol monophosphate 3-phosphatase activity GO:0052832 9.46 IMPA2 IMPA1
3 inositol monophosphate 1-phosphatase activity GO:0008934 9.26 IMPA2 IMPA1
4 inositol monophosphate phosphatase activity GO:0052834 8.8 IMPA2 IMPA1

Sources for Bipolar Disorder

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....